← Back to guidelines
Cardiology34 papers

Sialidosis

Last edited: 4/15/2026

Overview

Sialidosis is a rare autosomal recessive lysosomal storage disorder caused by deficiencies in alpha-N-acetyl neuraminidase (NEU1), leading to the accumulation of sialylated glycoconjugates. It manifests in two types: Type I with later onset and milder symptoms, and Type II with early-onset severe manifestations including systemic organ involvement 13.

Diagnosis

  • Clinical Presentation: Coarse facies, hepatosplenomegaly, refractory ascites, respiratory insufficiency, and cardiovascular dysfunction 13.
  • Biochemical Tests: Urinary oligosaccharide analysis showing abnormal patterns 3.
  • Enzyme Assays: Isolated deficiency of alpha-N-acetylneuraminidase (sialidase) in fibroblasts 3.
  • Molecular Analysis: Genetic mutations in NEU1 or PPCA genes, confirming enzyme complex deficiencies 23.
  • Management

  • Supportive Care: Intensive care management for respiratory and cardiovascular support 13.
  • Symptom-Specific Interventions: Addressing ascites and other organ-specific complications as they arise 3.
  • No Specific Pharmacological Treatment: Current evidence does not support specific drug treatments beyond supportive care 123.
  • Special Populations

  • Pediatrics: Neonatal cases present with severe symptoms including refractory ascites and early mortality 3.
  • Cardiovascular Involvement: Early-onset cardiovascular dysfunction noted in neonatal Type II sialidosis 1.
  • Key Recommendations

  • Genetic Testing for NEU1 and PPCA Mutations: Essential for confirming the diagnosis and understanding the molecular basis (Evidence: Moderate 23).
  • Comprehensive Multidisciplinary Support: Essential for managing systemic manifestations, particularly in neonates (Evidence: Expert opinion 13).
  • Monitoring and Management of Cardiovascular Involvement: Early recognition and intervention crucial in Type II sialidosis (Evidence: Weak 1).
  • References

    1 Prasanna P, Sriram CS, Rodriguez SH, Kohli U. Cardiovascular involvement in alpha-n-acetyl neuraminidase deficiency syndromes (sialidosis type I and II). Cardiology in the young 2021. link 2 Malvagia S, Morrone A, Caciotti A, Bardelli T, d'Azzo A, Ancora G et al.. New mutations in the PPBG gene lead to loss of PPCA protein which affects the level of the beta-galactosidase/neuraminidase complex and the EBP-receptor. Molecular genetics and metabolism 2004. link 3 Sergi C, Beedgen B, Kopitz J, Zilow E, Zoubaa S, Otto HF et al.. Refractory congenital ascites as a manifestation of neonatal sialidosis: clinical, biochemical and morphological studies in a newborn Syrian male infant. American journal of perinatology 1999. link

    Original source

    1. [1]
      Cardiovascular involvement in alpha-n-acetyl neuraminidase deficiency syndromes (sialidosis type I and II).Prasanna P, Sriram CS, Rodriguez SH, Kohli U Cardiology in the young (2021)
    2. [2]
      New mutations in the PPBG gene lead to loss of PPCA protein which affects the level of the beta-galactosidase/neuraminidase complex and the EBP-receptor.Malvagia S, Morrone A, Caciotti A, Bardelli T, d'Azzo A, Ancora G et al. Molecular genetics and metabolism (2004)
    3. [3]
      Refractory congenital ascites as a manifestation of neonatal sialidosis: clinical, biochemical and morphological studies in a newborn Syrian male infant.Sergi C, Beedgen B, Kopitz J, Zilow E, Zoubaa S, Otto HF et al. American journal of perinatology (1999)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG